Kornimate/medical-research-clean huggingface dataset:
blood flow within active myofascial trigger points following massage

Conditions: Myofascial Pain; Tension-type Headache

Summary: the physiological response at the myofascial trigger point (mtrp) to massage is not known, yet would provide important objective evidence for a treatment effect and clarify the resolution process of a mtrp.

the physiological response at the myofascial trigger point (mtrp) to massage is not known, yet would provide important objective evidence for a treatment effect and clarify the resolution process of a mtrp. the long-term goal is to understand how therapeutic intervention affects the physiology of the mtrp. the objective of the proposed research is to assess, in a placebo controlled trial, the effectiveness of trigger point release massage (also known as ischemic compression) on blood flow at an active mtrp. the central hypothesis is that the contraction nodule of an active mtrp is characterized by an ischemic state comprised of reduced blood flow and subsequent dysregulation in carbohydrate metabolism. the investigators hypothesize that trigger point release (tpr) can positively impact blood flow leading to a change in high energy carbohydrate tension. the present study has been formulated, in part, from a preliminary study conducted by the investigators, which supports reduced blood flow and physiological disruption at active mtrps. the proposed research will provide a physiological basis for massage to corroborate subjective reports of reduced pain sensitivity, impart credibility to treatment techniques, and provide insight into a mechanism of action for healing the mtrp.

Eligibility criteria:
inclusion criteria: * chronic or episodic tension-type headache * active mtrp in upper trapezius * age 21-49 * bmi between 18.5-24.9 * either gender * any race or ethnicity exclusion criteria: * no or latent mtrp in the upper trapezius * migraine 4+/month * cluster headache * fibromyalgia * neurological disease (e.g. alzheimer's disease, parkinson's disease, muscular dystrophy, multiple sclerosis) * cardiovascular disease (e.g. prior heart attack or stroke) * diabetes * pregnancy * a bleeding disorder (self-report of hemophilia, known lack/deficiency of clotting factors, or presently °taking anti-coagulants (e.g. warfarin, coumadin)) * narcotic use * currently receiving massage * prior trigger point injection or needling therapies * allergy to lidocaine-type anesthetics such as lidocaine and prilocaine

Keywords: blood flow glucose lactic acid
the effect of biofeedback-based virtual reality game on children

Conditions: Pediatric Cancer

Summary: the needles of port catheters, which are often used in childhood cancer treatment, must be changed every 5-7 days, which causes pain, anxiety, and fear in children every 5-7 days in recent years, the usage of virtual reality has grown to distract children during port catheter needle insertion. but it's not always easy for children to switch their attention to something else. a good child distractor must be sensory-stimulating, developmentally appropriate, and highly interactive.

today, virtual reality applications have advanced, and software that provides biofeedback with breathing has improved engagement with the user. our aim in this study is to examine the effect of biofeedback-based virtual reality games on pair, fear and anxiety levels during insertion of port needle insertion in children. the randomized control trial design will be used, and the consort list will be used to guide the research. this study will be conducted at the 62 pediatric oncology patients (31 experiment/ 31 control) aged 6-12 years. this study will be carry out in a university hospital in istanbul, turkey between january 2023, and june 2023. the research data will collect from the children's self-reports and parents through a survey form and scales. children's pain will evaluate by the children and parent with wong-baker faces pain rating scale, child fear will evaluate by the children and parent with 'child fear inventory', and child anxiety will evaluate by the children and parent with 'child anxiety statement scale'.

Eligibility criteria:
inclusion criteria: * between the ages of 6-12, * requires venous access * diagnosed with childhood cancer, * volunteers with at least one venous access experience. exclusion criteria: * with neurodevelopmental delay, * difficulty in verbal communication * auditory or visual impairment * those who have used analgesics in the last 24 hours and have a history of needle phobia.

Keywords: port catheter pediatric oncology pain anxiety fear biofeedback virtual reality
trial to assess safety and efficacy of mor202 in anti-pla2r + membranous nephropathy (amn)

Conditions: Glomerulonephritis, Membranous; antiPLA2R Positive

Summary: this is an open-label, multicentre study to characterize the safety and efficacy of the human anti-cd38 antibody mor202 in adult subjects with in anti-pla2r antibody positive membranous nephropathy (newly diagnosed/relapsed/refractory)

after treatment subjects will be observed for up to 1 year. study sponsor, originally hi-bio, inc., is now hi-bio, a biogen company.

Eligibility criteria:
key inclusion criteria: * \> 18 to \< 80 years (at date of signing informed consent form \[icf\]). * urine protein to creatinine ratio (upcr) of ≥ 3.000 g/g or proteinuria ≥ 3.500 g/24 h from 24-h urine at screening * active anti-pla2r antibody positive mn in need of immunosuppressive therapy (ist) according to investigator judgement and diagnosed on the basis of a biopsy, archival biopsy acquired within 5 years prior to screening is acceptable. * estimated glomerular filtration rate ≥ 50 ml/min/1.73m² or ≥ 30 and \<50 ml/min/1.73m², and interstitial fibrosis and tubular atrophy score of less than 25% on a renal biopsy obtained within the last 6 months prior to start of screening. * not in spontaneous remission despite proper treatment with aceis, arbs (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. if the subject is intolerant to an acei or arb, the reason must be documented and approval obtained prior to enrolment. * systolic blood pressure bp ≤150 mmhg and diastolic bp ≤100 mmhg after 5 minutes of rest * vaccinated against pneumococcus within the last 5 years prior to date of signing informed consent (subjects may be vaccinated during screening to meet this criterion; interval to first dose of mor202 must be at least 14 days). * cohort 1 comprises newly diagnosed or relapsed subjects: serum anti-pla2r antibodies ≥50.0 ru/ml * cohort 2 comprises therapy refractory subjects: a subject did not achieve immunological remission after prior ist(s) as documented by the investigator and b subject is without promising standard therapeutic options as documented by the investigator (i.e. investigator expects efficacy or safety issues with remaining ist options) and c serum anti-pla2r antibodies ≥ 20.0 ru/ml measured at screening note: france will only enroll patients in cohort 2. key exclusion criteria: * hemoglobin \< 80 g/l. * thrombocytopenia: platelets \< 100.0 x 109/l. * neutropenia: neutrophils \< 1.5 x 109/l. * leukopenia: leukocytes \< 3.0 x 109/l. * hypogammaglobulinemia: serum immunoglobulins ≤ 4.0 g/l. subjects may receive supportive therapies to meet the above criteria * b-cells \< 5 x 106/l. * secondary cause of mn (e.g. systemic lupus erythematosus, medications, malignancies) * concomitant renal disease other than mn (e.g., diabetic renal disease, lupus nephritis, iga nephropathy).
risk level of suffering from traffic injury in primary health care: lesionat project

Conditions: Traffic Accident; Chronic Disease; Prevalence of Psychoactive Substances in Road Traffic; Relative Risk Estimation of Accident for Impaired Drivers

Summary: main objectives: * to know the distribution of risk elements of traffic injuries secondary objectives: * to study the distribution of risk elements related with the possibility of suffering from a ti in relation to medication, chronic health problems, and consumption of psychoactive substances (alcohol and others). * to know the relation between levels of perception of risk of suffering from a ti and the presence of chronic problems, medications, or consumption of psychoactive substances.

methodology: design: observational, transversal, and multicentric research field of study: 20 phc users from urban areas population of study: random consecutive sampling of ≥ 16 years old drivers with open medical history. measure's tools: two means for data collection: survey among health professionals with medical history and structured telephonic survey about behaviours and risk perceptions in drivers. variables: sociodemographic data, chronic pathologies related to ti, consumption of medications ,alcohol consumption (audit-c test), psychoactive substances consumption (self declared), level of perception of risk according to professionals. telephone survey: class and age of driving license, type of roads, weekly driving time, safety behaviours, record of collisions/injuries in last year,self perception of health level(sf-12) andself perception of risk level. an descriptive analysis of population will be performed, a distribution of risk elements associated to ti will be described through bivariant analyses, and for describing the factors associated to perceived risk levels a linear regression multiple model will be built.

Eligibility criteria:
inclusion criteria: * 16 years old or more * catalan and/or spanish language speakers * drivers with driver license * participation accepted by the patient exclusion criteria: * patients who do not have contact phone number. * patients who do not answer up to 3 phone calls * patients with severe mental or physical health disorder

Keywords: injuries traffic injuries preventive medicine observational studies primary care
computed tomography coronary angiography (ctca) and coronary flow in stenosis analysis

Conditions: Coronary Artery Disease

Summary: the investigators' rationale was to evaluate whether a 64-slice ct scanner allows accurate measurement of computed tomographic changes in coronary artery flow profiles and whether ct flow measurements are suitable for classifying the significance and hemodynamic relevance of a stenosis and thereby supplement as a functional parameter for morphological stenosis analysis.

a total of 50 patients prospectively underwent computed tomography coronary angiography (ctca) in a multidetector ct scanner (brilliance 64, philips) ± 1 day before or after invasive coronary angiography (ica). immediately thereafter, 2 radiologists reviewed the imaging data to detect any vessel segments with morphology poorly evaluable by ctca. a locally constant cyclical measurement was acquired in these coronary arteries in breath-hold technique during the passage of a 50ml bolus of contrast media. for analysis, time-density curves of the bolus passage were registered in the coronary artery and the aorta (internal reference), the up-slopes were determined and correlated with each other. the results were compared with the ica findings.

Eligibility criteria:
inclusion criteria: * clinically known or presumed cad * age \> 50 years * hospitalization for invasive coronary angiography * sinus rhythm * written informed consent by the patient to participate in the study after comprehensive presentation of the facts exclusion criteria: * age \<= 50 years * contraindications to contrast media administration (medical history of iodine allergy, nephropathy, latent or manifest hyperthyroidism) * arrhythmias * dyspnea at rest, acute unstable angina pectoris, acute myocardial infarction * pregnancy * implanted pacemaker * unwillingness of patient to consent to the study

Keywords: coronary artery stenosis
a study of gk activator (2) in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus Type 2

Summary: this study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral gk activator (2), compared to placebo, in patients with type 2 diabetes mellitus. the anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients 30-75 years of age; * type 2 diabetes mellitus for \>3 months before screening; * treatment-naive, inadequately controlled diabetes despite diet and exercise, or inadequately controlled diabetes in patients on monotherapy or combination therapy (maximum of 2 oral anti-hyperglycemic medications). exclusion criteria: * type 1 diabetes mellitus; * women who are pregnant, breast-feeding or not using adequate contraceptive methods.
are the continuous glucose monitoring systems able to improve long term glycaemic control in type 1 diabetic patients?

Conditions: Type 1 Diabetes

Summary: the "capteur evadiac" study group, composed of french and belgian diabetologists, has designed a 1 year randomized controlled multicenter study in order to define what should be the best clinical way of using continuous glucose monitoring in the long term to improve metabolic control in uncontrolled type 1 diabetes patients.

the primary objective of the study is to determine whether patients with chronically poor glycaemic control as evidenced by hba1c \>= 8% twice can achieve improved metabolic control using during one year cgm together with educative program about insulin adaptation doses compared to conventional self monitoring finger sticks with educative program about insulin adaptation doses alone.

Eligibility criteria:
inclusion criteria: * type 1 diabetes for ≥ 12 months or more (including cpeptide negative secondary diabetes) * children between 8 and 18 years old * adults between 18 and 60 years old * patients treated with basal-bolus insulin regimens, pump or multiple daily injection, only with analogs, for at least 6 months * performing at least 2 finger sticks glucose controls per day * able and motivated to use the device * hba1c ≥ 8% twice with hplc method(dca 2000 excluded) * written informed consent obtained prior to enrollment in the study exclusion criteria: * blindness or impaired vision so the screen cannot be recognized * allergy to sensor * active proliferative retinopathy not stabilized by laser or vitrectomy occurence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during study * treatment with systemic corticosteroid or medication known to influence insulin sensitivity in the 3 months prioir to visit 1 * pregnancy * manifest psychiatric disturbance * presence of any conditions (medical, including clinically significant abnormal laboratory test, psychological, social or geographical) actuel or anticipated that the investigators feels would compromise the patient safety or limit his/her successful participation in the study. * hemoglobinopathy that interfers with hba1c measurement

Keywords: type 1 diabetes real time continuous glucose monitoring system hba1c navigator®
efficacy of mydriatic drops in premature infants

Conditions: Retinopathy of Prematurity

Summary: because of the neonatologists reported that some infants had suffered from vomiting, bradycardia, hypotonia, and aspiration risk about 30-60 minutes after the fundus examination in the intensive care unit. the investigators observed the pupil dilation effects and side effects of tipple instillation of phenylephrine 2.5% plus tropicamide 0.5% ophthalmic drop combination which the investigators routinely used in rop examination.

purpose: to determine effect and vital change after topical application of phenylephrine 2.5% and tropicamide 0.5% three times for retinopathy of prematurity (rop) examination in preterm infants. methods: pupillary diameter, blood pressure, pulse rate, and oxygen saturation were monitored before, and after up to 24 hours 60 rop screening examinations.

Eligibility criteria:
inclusion criteria: * infants who were first rop examinations * infants born before 32 weeks. exclusion criteria: * developmental ocular and/or systemic anomalies. * drug use that can affect vital values * unstable general condition * food intolerance * recurrent vomiting.
cci-779 in treating patients with relapsed or refractory chronic lymphocytic leukemia

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia

Summary: this phase ii trial is studying how well cci-779 works in treating patients with relapsed or refractory chronic lymphocytic leukemia. drugs used in chemotherapy, such as cci-779, work in different ways to stop cancer cells from dividing so they stop growing or die

objectives: i. determine the activity of cci-779 in patients with relapsed, refractory, or transformed chronic lymphocytic leukemia. outline: patients are stratified according to disease (relapsed or refractory chronic lymphocytic leukemia \[cll\] vs transformed cll). patients receive cci-779 iv over 30 minutes on days 1, 8, 15, and 22. treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. patients achieving an objective response may receive 3 consolidation courses of therapy.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic lymphocytic leukemia (cll) * relapsed, refractory, or transformed disease * relapsed disease defined as symptomatic loss of a prior partial or complete response to a regimen containing a purine analog and/or a monoclonal antibody and evidence of disease progression * primary resistant disease defined as failure to achieve an objective response to a regimen containing a purine analog and/or a monoclonal antibody * transformed cll (richters transformation), must meet both of the following criteria: * histologically confirmed lymphoma * measurable disease * no cns disease * performance status - ecog 0-2 * bilirubin ≤ 2 mg/dl (unless elevated due to gilbert's disease) * sgot and sgpt \< 3 times upper limit of normal * creatinine ≤ 2 mg/dl (unless due to organ leukemic involvement) * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * hiv-positive patients allowed provide cd4 counts are normal and no aids-defining disease is present * no history of allergic reactions attributed to compounds of similar chemical or biological composition to cci-779 * no ongoing or active infection * no psychiatric illness or social situation that would preclude study compliance * no other concurrent uncontrolled illness * see disease characteristics * no concurrent prophylactic hematopoietic colony-stimulating factors * see disease characteristics * more than 2 weeks since prior cytotoxic chemotherapy and recovered * more than 2 weeks since prior radiotherapy and recovered * no other concurrent investigational or antitumor agents * no other concurrent cytotoxic agents * no concurrent combination antiretroviral therapy for hiv-positive patients
carbon monoxide-saturated medium for islet isolation

Conditions: Chronic Pancreatitis

Summary: the goal of this study is to determine whether harvesting islets using carbon monoxide (co)-saturated mediums can protect islet cell from death after autologous islet transplantation in patients with chronic pancreatitis.

investigators plan to harvest human islets using carbon monoxide-saturated mediums. survival and function of transplanted islets will be compared with islets harvested using regular mediums.

Eligibility criteria:
inclusion criteria: 1. chronic pancreatitis patient selected for total pancreatectomy and islet autotransplantation. 2. age between 18-69. exclusion criteria: 1. had prior pancreatic surgeries. note: the study was initially designed only to enroll diabetes free patients. to increase enrollment, we extended the inclusion criteria by allowing patients who are pre-diabetic to participate the study. this revision was approved by the musc irb on 11/10/2015.
postoperative inflammation and recovery after tracheostomy

Conditions: Tracheostomy Complication; Inflammation; Post-operative Complications

Summary: the main purpose of this study is to examine if there are differences in postoperative inflammation following percutaneous dilatation tracheostomy versus surgical tracheostomy in intensive care unit patients.

are there differences between the two arms in plasma concentrations of inflammatory mediators (tnf-alfa, interleukin 1, 6, 10) at 24 hrs following the start of the surgical procedure? are there differences between the two arms in the incidence of postoperative complications (i.e. bleeding, incidence of stomal infections, tracheal tube dislocation, airway compromisation), postoperative pulmonary infection (during the stay in the icu) and pulmonary function (fev1, dynamic complicance, oxygen demand, time to weaning off the ventilator: all measured daily during the icu-stay), postoperative mobilization (time to mobilization to sitting, standing and walking, respectively)?

Eligibility criteria:
inclusion criteria: patients in whom a tracheostomy is indicated (i.e. anticipated need of mechanical ventilation for \>7 days or anticipated risk for complicated extubation, e.g. anatomical signs of a compromised airway, reduced level of consciousness. adults over 18 years. participants who are suitable for both surgery techniques. exclusion criteria: children under 18 years, pregnancy and participants with anatomical defects that exclude them from percutaneous dilatation tracheostomy.
acute exposure of simulated hypoxia on pulmonary artery pressure and right heart function (echo) under exercise

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to simulated altitude (fio2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart function (echo) under exercise.

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, six-minute walk test (6mwt), pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested under simulated altitude (fio2: 15.1% with the "amc altitrainer") and shamed altitude with the same device. several times within the exposure, the pulmonary artery pressure and the right heart function will be assessed by echo under exercise.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mean pulmonary artery pressure (mpap) ≥ 25 mmhg along with a pulmonary artery wedge pressure (pawp) ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting partial oxygen pressure (pao2) ≤7.3 kilopascal (kpa) corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, high-altitude pulmonary edema (hape), etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: simulated altitude pulmonary artery pressure echocardiography right heart function exercise